LLY today

$1437.29+$5.00 (+0.35%)close Nov 11, 2026

Trend

DailyUptrend (confirmed)

4 hourBullish

1 hourBullish

15 minBullish

5 minConsolidating

Daily trend turns down below $1113.29

Key levels

Resistance$1449.68

Support$1333.22

Support$1215.00

About Eli Lilly

Eli Lilly is a pharmaceutical company that discovers, develops, manufactures, and markets human medicines. Its products cover cardiometabolic health, oncology, immunology, and neuroscience, including treatments for diabetes, obesity, cancer, and Alzheimer's disease. It sells to wholesalers, pharmacies, healthcare providers, and insurers in roughly 90 countries, with manufacturing in the United States, Europe, and Asia.

Based on the company's 10-K filed Feb 12, 2026.

NYSE · Healthcare

ELI LILLY & Co (LLY)

$1437.29+5.00 (+0.35%)

BUYGrade: B+Risk: LOW

1D 5D1M1Y 5Y MaxSign up for all timeframes

High1440.47

Low1414.37

Open1418.08

Volume1.74M

Avg Vol2.49M

VWAP1426.90

30d High1437.29

30d Low1142.85

30d Chg+25.00%

See full chart with real-time data

What Is the Price Target for LLY?

SEPT Low Target

$940.00

SEPT Mid Target

$1573.00

SEPT High Target

$1700.00

Analyst Consensus

$1573.00

Current: $1437.14Upside: +9.4%Confidence: 85%Method: Analyst Consensus

Is LLY a Buy or Sell Right Now?

Investability Score

BUY12-18 months

News summary · last 30 days

Oct 29▲ UpEarnings5 articles

Eli Lilly shares rose 2.99% to close at $1372.59, trading between a low of $1330.00 and a high of $1408.38 on volume of 3,521,450. The move followed the company's Q3 2026 earnings release, which it described as solid, alongside news that Mounjaro sales jumped 65% to $10.7 billion on strong demand for the diabetes and weight-loss drug. The company also disclosed $303 million in one-time Q3 costs, bringing its nine-month total to $1.3 billion, driven by intangible asset impairments, acquisition-related expenses and litigation. Despite those charges, the bullish Mounjaro figure and upbeat earnings framing appear to have driven the positive price action.

Oct 28▲ UpProductEarnings5 articles

Eli Lilly shares closed at $1288.93, up 1.61% on volume of about 1.49 million shares, as investors digested positive late-stage trial results for retatrutide. The company reported that retatrutide met its goals in a phase 3 type 2 diabetes study and helped patients lose more than twice as much weight as Ozempic in a separate comparison trial, both bullish signals for its obesity and diabetes pipeline. The stock traded between $1260.34 and $1299.43 during the session. With Lilly also set to report quarterly results on Thursday, the trial data may keep sentiment constructive into the earnings release.

Oct 16▲ UpFdaContract3 articles

Eli Lilly shares closed essentially flat at $1257.03, up just 0.08% on the day, despite two positive regulatory developments. The company announced that its GLP-1 pill received a key European backing, with the EMA's CHMP issuing a positive opinion recommending marketing authorization for Foundayo for type 2 diabetes and weight management. Additionally, Lilly disclosed a 19.9% stake in TRex Bio, investing $12.3 million in its IPO, though this was viewed as a noise-level event. The European regulatory news is a medium-impact bullish catalyst that could support the stock in upcoming sessions, but today's muted price action suggests the market had largely anticipated the decision. Overall, the news flow leans positive, signaling potential upward momentum.

Thesis

•Revenue growing 44.7% YoY with ACCELERATING trend — accelerating momentum.

AI-Powered Trading Signals

Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for LLY.

Start Free Trial →

Is LLY Overvalued or Undervalued?

Valuation Verdict

FAIR

Methods Used

P/E Forward, P/B, PEG, Analyst Consensus

Fair Value

$1475.84

Moat Score

NARROW

6/9

Piotroski Score

N/A

Altman Z-Score

What Is Smart Money Doing with LLY?

Insider Signal

NEUTRAL

0 buys / 1 sells (90d)

Congress Signal

BUYING

9 buys / 11 sells (90d)

Institutional

N/A

Short Squeeze Risk

MEDIUM

Signal: NEUTRAL

Recent Insider Activity

Name	Title	Type	Shares	Value	Date
Jonsson Patrik	officer	Sale	704	-	Nov 10, 2026
Ricks David A	director officer	Sale	23,538	-	Nov 3, 2026
Skovronsky Daniel	officer	Sale	119	-	Nov 2, 2026
Hakim Anat	officer	Sale	5,000	$7.0M	Nov 2, 2026
Brown Adrienne S	officer	Buy	2,530	-	Nov 1, 2026
Brown Adrienne S	officer	Sale	1,098	$1.6M	Nov 1, 2026
Custer Kenneth L.	officer	Buy	3,220	-	Nov 1, 2026
Custer Kenneth L.	officer	Sale	1,425	$2.0M	Nov 1, 2026
Dozier Eric	officer	Buy	2,300	-	Nov 1, 2026
Dozier Eric	officer	Sale	1,019	$1.4M	Nov 1, 2026

Track Smart Money Across 4,000+ Stocks

Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.

See All Smart Money Signals →

LLY Growth Story

Revenue YoY

44.7%

3yr Revenue CAGR

31.7%

EPS Growth YoY

95.99%

FCF Growth YoY

N/A%

Revenue Trend

ACCELERATING

Dark Pool Trades for LLY

PREVIEW

SEPT Investing tracks real-time dark pool institutional trades for LLY, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.

Time	Price	Size	Value	Side
21:57:15	$1437.29	2,203	$$3.2M	SELL
21:43:29	$1437.29	1,638	$$2.4M	BUY
21:28:26	$1437.29	12,474	$$17.9M	BUY
21:04:07	$1437.29	1,230	$$1.8M	SELL
21:04:07	$1437.29	1,282	$$1.8M	SELL

5 dark pool trades shown · $$27.1M preview volume

Real-time institutional flow, block trades, and net positioning

See all dark pool activity

Options Flow for LLY

PREVIEW

SEPT Investing provides real-time options flow tracking for LLY, including unusual sweep detection, block trades, and dealer positioning. Each trade shows strike, expiry, premium, implied volatility, and greek values for informed decision-making.

Type	Strike	Expiry	DTE	Premium	Size	Trade
CALL	$1500	Nov 13	2	$$65	1	SWEEP
CALL	$1320	Nov 20	9	$$596.8K	50	BLOCK
CALL	$1260	Nov 20	9	$$887.8K	50	BLOCK
CALL	$760	Dec 17	401	$$217.5K	3	BLOCK
CALL	$760	Jan 21	436	$$219.1K	3	BLOCK

5 options trades shown · 100% calls

Unusual activity, GEX levels, max pain, and dealer positioning

See full options flow

What Traders Are Saying About LLY

1 posts

SEPT Investing hosts an active community of 3,500+ traders sharing real-time analysis, trade setups, and market discussion for LLY. Join verified traders discussing price action, dark pool alerts, options flow, and AI-powered market intelligence.

SEPT InvestingVERIFIED156d ago

Zone Setup -- $LLY (ELI LILLY & Co) Price: $1132.54 | Zone: $1131.03 to $1166.01 Conviction: HIGH | Analyst upside: +9.5% Major volume event today — setup forming. Strong positive news (8+ vs 3-)

1232 views

Join 3,500+ traders discussing LLY in real-time

Trade ideas, setups, dark pool alerts, and AI-powered analysis

Join the discussion

Full AI Research Report

SEPT's Trading AI has generated a free, downloadable PDF research report for ELI LILLY & Co (LLY) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.

Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (8 articles analyzed), and SEC filing intelligence...

AI-Powered Trading Signals.

Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.

Try SEPT Free for 7 Days →

LLY — frequently asked questions

What is LLY stock price today?

ELI LILLY & Co (LLY) is at $1437.29, up 0.35% (+$5.00) at the Nov 11, 2026 close.

Why is LLY stock moving today?

Latest LLY news — Nov 11, 2026: Eli Lilly says Taltz plus Zepbound helped psoriatic arthritis patients over a longer period in a study · Nov 11, 2026: Washington pressure raises short-term revenue risk for Eli Lilly and Gilead

Why did LLY stock move on Oct 29, 2026?

What is the LLY price target?

The average analyst price target for LLY is $1573.00, ranging from $940 to $1700, based on 16 analysts. Latest: Jefferies maintains on Nov 9, 2026.

What do analysts rate LLY?

Analyst ratings for LLY: 26 Buy, 3 Hold, 2 Sell — consensus Buy.

Did LLY beat earnings?

LLY last reported on Oct 29, 2026: EPS $7.48 vs $5.68 expected — a beat of 31.7%.

What is LLY's P/E ratio?

LLY trades at a P/E of 45.6 vs a Healthcare average of 17.3.

Does LLY pay a dividend?

Yes. LLY's dividend yield is 0.56%.

What are LLY support and resistance levels?

Support: $1333.22, $1215.00, $1131.21. Resistance: $1449.68.

What are insiders doing with LLY?

Insider activity: NEUTRAL, 0 buys and 1 sells in the last 90 days.

What is the latest news on LLY?

Nov 11, 2026: Eli Lilly says Taltz plus Zepbound helped psoriatic arthritis patients over a longer period in a study · Nov 11, 2026: Washington pressure raises short-term revenue risk for Eli Lilly and Gilead · Nov 11, 2026: Lilly reports Phase 3b results for Taltz and Zepbound